Drug Interactions between delavirdine and st. john's wort
This report displays the potential drug interactions for the following 2 drugs:
- delavirdine
- st. john's wort
Interactions between your drugs
delavirdine St. John's wort
Applies to: delavirdine and st. john's wort
GENERALLY AVOID: Coadministration with St. John's wort may significantly reduce the plasma concentrations of certain antiretroviral agents such as nonnucleoside reverse transcriptase inhibitors (NNRTIs), and CCR5 coreceptor antagonists. The mechanism is induction of CYP450 3A4 metabolism by constituents of St. John's wort. In eight healthy volunteers, St. John's wort (300 mg, standardized to 0.3% hypericin, three times a day for 14 days) decreased the 8-hour area under the plasma concentration-time curve (AUC) and extrapolated 8-hour trough of indinavir (800 mg every 8 hours for 4 doses) by a mean of 57% and 81%, respectively, compared to administration of indinavir alone. All participants showed a reduction in the indinavir 8-hour postdose concentration ranging from 49% to 99%. The interaction was also suspected as the cause of low nevirapine plasma levels in five HIV patients who used St. John's wort while being treated with nevirapine and two nucleoside reverse transcriptase inhibitors.
MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, patients treated with antiretroviral agents should avoid using St. John's wort. Patients should be advised to consult with their caregivers before using any herbal or alternative medicines.
References (21)
- (2001) "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical
- (2001) "Product Information. Crixivan (indinavir)." Merck & Co., Inc
- (2001) "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc
- (2001) "Product Information. Agenerase (amprenavir)." Glaxo Wellcome
- Acosta EP, Henry K, Baken L, Page LM, Fletcher CV (1999) "Indinavir concentrations and antiviral effect." Pharmacotherapy, 19, p. 708-12
- FDA (2001) FDA public health advisory on risk of drug interactions with St John's wort and indinavir and other drugs. URL: http://www.fda.gov/cder/drug/advisory/sjwort.htm
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000) "Indinavir concentrations and St John's wort." Lancet, 355, p. 547-8
- Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) "St John's Wort: Effect on CYP3A4 activity." Clin Pharmacol Ther, 67, p. 451-7
- Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, DelGiudice P, Montagne N, Schapiro JM, Dellamonica P (2000) "Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study." Aids, 14, p. 1333-9
- (2001) "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical
- (2001) "Product Information. Fortovase (saquinavir)." Roche Laboratories
- de Maat MM, Hoetelmans RM, Mathot RA, et al. (2001) "Drug interaction between St John's wort and nevirapine." AIDS, 15, p. 420-1
- Durr D, Stieger B, KullakUblick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) "St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4." Clin Pharmacol Ther, 68, p. 598-604
- Veldkamp AI, Weverling GJ, Lange JM, et al. (2001) "High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals." AIDS, 15, p. 1089-95
- Mangum EM, Graham KK (2001) "Lopinavir-Ritonavir: a new protease inhibitor." Pharmacotherapy, 21, p. 1352-63
- Izzo AA, Ernst E (2001) "Interactions between herbal medicines and prescribed drugs: a systematic review." Drugs, 61, p. 2163-75
- (2003) "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb
- (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline
- (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
- (2006) "Product Information. Prezista (darunavir)." Ortho Biotech Inc
- (2007) "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group
Drug and food interactions
St. John's wort food
Applies to: st. john's wort
GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.
References (1)
- Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.